Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.

Scientific Posters

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Viral clearance from conventional to unconventional process steps in Biologics

Learn how viral clearance from unconventional steps can add value to the total viral clearance independently or along with conventional process steps.

Predicting genotoxicity and carcinogenicity of drugs and chemicals using using OECD QSAR, DEREK Nexus® and TEST

A comparison of in silico prediction of genotoxicity and carcinogenicity of drugs, with the results obtained from curated data in published literature.

Robust and high-yielding platform process for plasmid DNA production

How Syngene scientists developed a platform process for plasmid DNA production with high titers of > 1 g/L upstream with >25% recovery downstream.

Process development and scale-up of highly challenging biomolecules

Three case studies on downstream platform process development for antibody fragments, three broadly neutralizing antibodies (bNAbs) against HIV, and a new class of regenerative implant used for treating a degenerative disease.

Mycoplasma Contamination Detection in Biopharmaceuticals

Presenting impact of Mycoplasma contamination, available testing methods, and why Syngene prefers NAT-based Mycoplasma detection method over other methods.

Targeted Protein Modulators – Cellular to ADME to PK/PD models and correlations

Presenting the cellular translation to degradation and functional response across different assay platforms using a PROTAC tool SynTAC-ERD, an Estrogen Receptor (ER) degrader.

In silico toxicity prediction using Derek Nexus for predicting skin sensitization, phototoxicity, hepatotoxicity and in vitro hERG inhib

In silico toxicity evaluation using Derek® Nexus for quicker and cost-effective screening for skin sensitization phototoxicity, hepatotoxicity, and in vitro hERG channel inhibition

Chromatography based purification of retro virus spikes

Presenting the data for purification of Retro virus using ion exchange chromatography where the condition for purification was optimized.

Early discovery due diligence of immuno target through multi pronged approaches

Our approach to informed decision-making during early discovery stage to create novel, best-in-class drugs.

Effect of Container Closure Systems on Stability of Pharmaceutical Products

Case studies on how Syngene handled unique problems in Stability Testing arising from packaging material.

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details